IVERIC bio, Inc. - FORM 10-K - EX-23.1 - EXHIBIT 23.1 - March 5, 2018

Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - IVERIC bio, Inc.opht12312017exhibit321.htm
10-K - 10-K - IVERIC bio, Inc.opth1231201710-k.htm
EX-32.2 - EXHIBIT 32.2 - IVERIC bio, Inc.opht12312017exhibit322.htm
EX-31.2 - EXHIBIT 31.2 - IVERIC bio, Inc.opht12312017exhibit312.htm
EX-31.1 - EXHIBIT 31.1 - IVERIC bio, Inc.opht12312017exhibit311.htm
EX-10.22 - EXHIBIT 10.22 - IVERIC bio, Inc.exhibit10_22xbwoodxseparat.htm
EX-10.11 - EXHIBIT 10.11 - IVERIC bio, Inc.exhibit10_11xophthotechxfi.htm


Exhibit 23.1 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 
        We consent to the incorporation by reference in the following Registration Statements:

(1)
Registration Statement (Form S-8 No. 333-219656) pertaining to the 2013 Stock Incentive Plan of Ophthotech Corporation effective August 3, 2017,

(2)
Registration Statement (Form S-8 No. 333-211916) pertaining to the 2016 Employee Stock Purchase Plan of Ophthotech Corporation effective June 8, 2016,

(3)
Registration Statement (Form S-8 No. 333-208893) pertaining to the 2013 Stock Incentive Plan and Inducement Stock Option Grant of Ophthotech Corporation, effective January 6, 2016, 

(4)
Registration Statement (Form S-8 No. 333-202438) pertaining to the 2013 Stock Incentive Plan and inducement stock options of Ophthotech Corporation, effective March 2, 2015, 

(5)
Registration Statement (Form S-8 No. 333-193694) pertaining to the 2013 Stock Incentive Plan of Ophthotech Corporation, effective January 31, 2014, 

(6)
Registration Statement (Form S-8 No. 333-191767) pertaining to the 2013 Stock Incentive Plan and Amended and Restated 2007 Stock Incentive Plan of Ophthotech Corporation, effective October 16, 2013,

of our reports dated March 5, 2018, with respect to the financial statements of Ophthotech Corporation, and the effectiveness of internal control over financial reporting of Ophthotech Corporation included in this Annual Report (Form 10-K) of Ophthotech Corporation for the year ended December 31, 2017.

/s/ Ernst & Young LLP


MetroPark, New Jersey


March 5, 2018
 




IVERIC bio, Inc. Reports